Abstract：Objective: To explore the correlation between tissue microRNA-219 (miR-219), microRNA-34a (miR-34a), and DC-STAMP domain containing 1-antisense 1 (DCST1-AS1) with the clinicopathological features in non-small cell lung cancer (NSCLC), as well as their diagnostic value. Methods: A total of 120 NSCLC patients admitted to the Nuclear Industry 416 Hospital from May 2022 to May 2024 were enrolled. The cancerous tissues and adjacent tissues were taken, and the expression of miR-219, miR-34a, and DCST1-AS1 in the cancerous tissues and adjacent tissues was determined by quantitative reverse-transcription polymerase chain reaction (qRT-PCR). The expression of miR-219, miR-34a, and DCST1-AS1 in patients with different clinicopathological features was compared. Spearman correlation coefficient analysis was used to analyze the correlation between the expression of miR-219, miR-34a, and DCST1-AS1 in tissues and clinicopathological features. Receiver operating characteristic (ROC) curve, area under the curve (AUC), and decision curve analysis (DCA) were used to analyze the diagnostic value and clinical net benefit of miR-219, miR-34a, and DCST1-AS1 in NSCLC. Results: The expression of miR-219 (0.68±0.20 vs 1.00±0.30) in the cancerous tissue of the study subjects was significantly lower than that in the adjacent tissue, while the expressions of miR-34a (1.31±0.39 vs 1.00±0.28) and DCST1-AS1 (1.39±0.42 vs 1.05±0.31) were significantly higher than those in the adjacent tissue (t=9.722, 7.073, 7.135, P<0.05). The tumor, node, metastasis (TNM) staging,tumor differentiation, and lymph node metastasis were closely associated with the expression of tissue miR-219 (r = -0.644, 0.650, -0.601), miR-34a (r = 0.613, -0.604, 0.627), and DCST1-AS1 (r = 0.605, -0.620, 0.616) (P<0.05). The AUC of the combined diagnosis of miR-219, miR-34a, and DCST1-AS1 for NSCLC was 0.934 (0.895-0.962), with the highest clinical net benefit rate within the range of 0.2~1.0. Conclusion: Tissue miR-219, miR-34a, and DCST1-AS1 expression are closely associated with clinicopathological features of NSCLC patients. The combination of the three can be used as a reliable scheme for the diagnosis of NSCLC, providing an objective evidence for precise diagnosis and treatment.
李晓琴, 李月, 刘玉兰, 于映红, 胡婕, 陈仕高, 程双华. 组织miR-219 miR-34a DCST1-AS1与非小细胞肺癌临床病理特征相关性及诊断价值[J]. 河北医学, 2025, 31(2): 291-296.
LI Xiaoqin, LI Yue, LIU Yulan, et al. Correlation of Tissue MiR-219 MiR-34a and DCST1-AS1 with the Clinicopathological Features in Non-small Cell Lung Cancer and its Diagnostic Value. HeBei Med, 2025, 31(2): 291-296.
[1] Ettinger DS,Wood DE,Aisner DL,et al.NCCN guidelines insights:non-small cell lung cancer,version 2.2023[J].Natl Compr Canc Netw,2023,21(4):340-350. [2] Zhang Y,Mi YY,He CH.2-methoxyestradiol restrains non-small cell lung cancer tumorigenesis through regulating circ_0010235/miR-34a-5p/NFAT5 axis[J].Thorac Cancer,2023,14(22):2105-2115. [3] Yao ZT,Yang YM,Sun MM,et al.New insights into the interplay between long non-coding RNAs and RNA-binding proteins in cancer[J].Cancer Commun (Lond),2022,42(2):117-140. [4] 唐莉,韦达,严枫.长链非编码RNA树突状细胞-特异性跨膜蛋白域包含1-反义链1通过α-烯醇化酶促进三阴性乳腺癌细胞的增殖与侵袭[J].中华实验外科杂志,2021,38(4):606-609. [5] 中国抗癌协会肿瘤病理专业委员会,中国抗癌协会肺癌专业委员会,中国临床肿瘤学会非小细胞肺癌专家委员会.非小细胞肺癌PD-L1表达临床检测中国专家共识(2023版)[J].中华病理学杂志,2024,53(2):121-129. [6] 刘真,陈诚.紫杉醇3周给药联合顺铂化疗对非小细胞肺癌患者miR-564,miR-219表达及预后的影响[J].川北医学院学报,2023,38(1):122-125. [7] 杨佳,李娅娴,王莹莹,等.云南汉族人群 mircoRNA-149、mircoRNA-219、mircoRNA-let-7基因多态性与非小细胞肺癌发生和发展的相关性[J].昆明医科大学学报,2021,42(10):22-28. [8] 王韵,彭斐,宋姗,等.BSN-AS2竞争性结合miR-219a-5p影响NSCLC细胞增殖、迁移、侵袭及凋亡[J].现代肿瘤医学,2023,31(11):2026-2031. [9] Li J,Che LY,Xu C,et al.XIST/miR-34a-5p/PDL1 axis regulated the development of lung cancer cells and the immune function of CD8+ T cells[J].Recept Signal Transduct Res,2022,42(5):469-478. [10] 李敏,李海新,陈艳红,等.血清miR-215和miR-34a表达水平与非小细胞肺癌患者术后复发或转移的关系[J].广东医学,2022,43(8):1016-1020. [11] Mehrzad N,Zamani MS,Rahimi A,et al.Methylation status of miR-34a and miR-126 in non-small cell lung cancer (NSCLC) tumor tissues[J].Iran Biomed,2024,28(1):53-58. [12] 李静,李志娜,田浩印,等.miR-134-5p,miR-34a,CCL20预测肺癌根治术后复发的价值[J].临床肺科杂志,2023,28(12):1798-1802. [13] 王琴,唐莉.LncRNA DCST1-AS1结合ALDOA促进三阴性乳腺癌细胞的侵袭[J].临床检验杂志,2020,38(12):894-898. [14] 邱丽君,张静怡,袁健珊,等.宫颈鳞状细胞癌组织LncRNA DCST1-AS1、LncRNA MCM3AP-AS1表达与增殖侵袭基因和预后的关系[J].现代生物医学进展,2024,24(10):1985-1990. [15] 郭晓丹,马振禹,王晨静,等.DCST1-AS1在非小细胞肺癌中的表达及其生物学作用[J].局解手术学杂志,2023,32(12):1035-1040.
2025, Vol. 31 
冀公网安备13080202000786号